美氯芬那酸抑制TRPM4可抑制钙依赖性触发心律失常
该研究结合体外电生理、钙成像及在体心电监测,发现TRPM4参与钙超载诱导的背景电流并调控细胞兴奋性。在两种钙依赖性促心律失常模型中,Trpm4-/-小鼠心律失常负荷降低;化合物筛选发现美氯芬那酸为TRPM4拮抗剂,10 µM可抑制钙超载诱导的背景电流,15 mg/kg以TRPM4依赖方式抑制CPVT相关心律失常。结论提示TRPM4是防治钙依赖性触发心律失常的新靶点。
要点
- TRPM4参与钙超载诱导的背景电流并调控细胞兴奋性。
- Trpm4-/-小鼠在两种钙依赖性模型中显示心律失常负荷降低。
- 美氯芬那酸抑制TRPM4,以TRPM4依赖方式减少CPVT相关心律失常。
核心结论
- TRPM4是防治钙依赖性触发心律失常的新靶点。
研究设计与样本
- 研究采用体外电生理、钙成像技术以及在生理和病理生理条件下的在体心腔内与遥测心电图测量。
- 使用两种不同的钙依赖性促心律失常模型及自由活动Trpm4-/-小鼠进行在体评估。
- 通过化合物筛选鉴定美氯芬那酸为TRPM4的有效拮抗剂。
主要发现
- 在两种钙依赖性促心律失常模型中,自由活动Trpm4-/-小鼠的心脏心律失常负荷降低。
- TRPM4参与钙超载诱导的长时程背景电流,从而在钙超载条件下调控细胞兴奋性。
- 10 µM美氯芬那酸抑制心室肌细胞中钙超载诱导的背景电流。
- 15 mg/kg美氯芬那酸以TRPM4依赖方式抑制儿茶酚胺敏感性多形性室性心动过速相关心律失常。
关键数值与推荐
- 10 µM美氯芬那酸抑制心室肌细胞钙超载诱导的背景电流。
- 15 mg/kg美氯芬那酸以TRPM4依赖方式抑制CPVT相关心律失常。
临床怎么用
- TRPM4可作为钙依赖性触发心律失常防治的潜在新靶点。
- 美氯芬那酸作为TRPM4拮抗剂,在动物模型中显示抗心律失常作用,尚需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Cardiac arrhythmias are a major factor in the occurrence of morbidity and sudden death in patients with cardiovascular disease. Disturbances of Ca2+ homeostasis in the heart contribute to the initiation and maintenance of cardiac arrhythmias. Extrasystolic increases in intracellular Ca2+ lead to delayed afterdepolarizations and triggered activity, which can result in heart rhythm abnormalities. It is being suggested that the Ca2+-activated nonselective cation channel TRPM4 is involved in the aetiology of triggered activity, but the exact contribution and in vivo significance are still unclear. METHODS AND RESULTS: In vitro electrophysiological and calcium imaging technique as well as in vivo intracardiac and telemetric electrocardiogram measurements in physiological and pathophysiological conditions were performed. In two distinct Ca2+-dependent proarrhythmic models, freely moving Trpm4-/- mice displayed a reduced burden of cardiac arrhythmias. Looking further into the specific contribution of TRPM4 to the cellular mechanism of arrhythmias, TRPM4 was found to contribute to a long-lasting Ca2+ overload-induced background current, thereby regulating cell excitability in Ca2+ overload conditions. To expand these results, a compound screening revealed meclofenamate as a potent antagonist of TRPM4. In line with the findings from Trpm4-/- mice, 10 µM meclofenamate inhibited the Ca2+ overload-induced background current in ventricular cardiomyocytes and 15 mg/kg meclofenamate suppressed catecholaminergic polymorphic ventricular tachycardia-associated arrhythmias in a TRPM4-dependent manner. CONCLUSION: The presented data establish that TRPM4 represents a novel target in the prevention and treatment of Ca2+-dependent triggered arrhythmias.
引用
- Vandewiele F, Pironet A, Jacobs G, et al. TRPM4 inhibition by meclofenamate suppresses Ca2+-dependent triggered arrhythmias. Eur Heart J. 2022. PMID: 35822895. doi:10.1093/eurheartj/ehac354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。